A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2001
11/01/2001	WO2001068693A8 A novel polypeptide, human cannabinoid receptor protein 7 and the polynucleotide encoding thereof
11/01/2001	WO2001043754A3 Pharmaceutical composition comprised of spider venoms, the production thereof, and its use for treating tumor diseases
11/01/2001	WO2001042431A3 Regulation of human mitochondrial deformylase
11/01/2001	WO2001042306A3 Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization
11/01/2001	WO2001041762A3 Valdecoxib compositions
11/01/2001	WO2001041761A3 Valdecoxib compositions
11/01/2001	WO2001038487A3 MOUSE ASPARTIC SECRETASE-1 (mASP1)
11/01/2001	WO2001037853A3 Methods and agents for the inhibition of smooth muscle cell proliferation
11/01/2001	WO2001036609A8 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
11/01/2001	WO2001036608A8 Reversibly inactivated acidified plasmin
11/01/2001	WO2001036604A3 Nucleic acids encoding endotheliases, endotheliases and uses thereof
11/01/2001	WO2001036457A3 Chlamydia antigens and corresponding dna fragments and uses thereof
11/01/2001	WO2001035986A3 Methods and compositions for modulating er-stress-induced cholesterol accumulation
11/01/2001	WO2001035974A3 Aplidine treatment of cancers
11/01/2001	WO2001034640A3 Peptide (virip) which inhibits a circulating virus in humans and the use thereof
11/01/2001	WO2001032866A3 Hybrid adaptor receptors
11/01/2001	WO2001032153A3 Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
11/01/2001	WO2001032133A3 Improved nit removal product
11/01/2001	WO2001030380A3 Methods and compositions for treatment of keratoconus using protease inhibitors
11/01/2001	WO2001030372A3 Pharmaceutical agent preparations
11/01/2001	WO2001029084A3 Novel human proteins and polynucleotides encoding the same
11/01/2001	WO2001029066A3 Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
11/01/2001	WO2001028500A3 Uses of antileukoprotease in carcinoma
11/01/2001	WO2001028356A3 Food supplement for increasing lean mass and strength
11/01/2001	WO2001023522A8 Compositions and methods for p53-mediated repression of gene expression
11/01/2001	WO2001021791A3 Stargazin-like neuronal ca2+-channel gamma subunit polypeptides
11/01/2001	WO2001017480A3 Methods and compositions for preventing and treating urinary tract disorders
11/01/2001	WO2001014318A3 New effectors of dipeptidyl peptidase iv for topical use
11/01/2001	WO2001012233A3 Sustained release formulation of a peptide
11/01/2001	WO2000075338A3 CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF
11/01/2001	WO2000053757A3 Promotion or inhibition of angiogenesis and cardiovascularization
11/01/2001	WO2000043036A3 Lipoprotein complexes and compositions containing them
11/01/2001	WO2000034483A3 Compounds and methods for treatment and diagnosis of chlamydial infection
11/01/2001	WO2000032632A9 Allo- and auto-reactive t-cell epitopes from rhesus protein and their use
11/01/2001	WO2000024780A9 Compositions and methods for treating polycystic kidney disease
11/01/2001	US20010037017 Obtaining cartilage tissue, homogenizing the tissue in the presence of chaotropic agents under condition that permits separation of proteins from proteolycans, separating proteins from proteoglycans, obtaining the proteins
11/01/2001	US20010037014 Thin mineralized collagen membrane comprises a homogeneous mineralized collagen composite consisting of 30%-70% collagen 30%-70% by weight of calcium phosphate minerals precipited from collagen slurry by soluble calcium and phosphate
11/01/2001	US20010036954 Use of calcium channel blocker optionally in the presence of a anti-hypertensive agent
11/01/2001	US20010036946 Antiinflammatory agents
11/01/2001	US20010036932 Cardiovascular disorders
11/01/2001	US20010036929 Dna repair
11/01/2001	US20010036927 Complexing
11/01/2001	US20010036925 Genetic engineering
11/01/2001	US20010036921 Osteopontin-derived chemotactic and inhibitory agents and uses therefor
11/01/2001	US20010036920 Method for treating papillomavirus infections
11/01/2001	US20010036918 Pharmaceutical composition
11/01/2001	US20010036917 Therapeutic agents
11/01/2001	US20010036916 Insoluble insulin compositions
11/01/2001	US20010036914 Use of polyamino acid derivatives as preserving agents, compositions comprising them and preserving process using them
11/01/2001	US20010036664 Graft-versus-host disease
11/01/2001	US20010036662 Genetic engineered nucleotide sequence
11/01/2001	US20010036635 Cancer screening
11/01/2001	US20010036625 Method for identifying compounds for treatment of insulin resistance
11/01/2001	US20010036502 Oil composition
11/01/2001	US20010036481 Modulation of release from dry powder formulations
11/01/2001	US20010036480 Particulate drug-containing products and method of manufacture
11/01/2001	US20010036462 Enhancing immunology response
11/01/2001	US20010036459 Cytotoxicity; therapeutic antibody
11/01/2001	US20010036456 Administering Protein C
11/01/2001	US20010036455 Administering neuraminidase
11/01/2001	US20010036454 Transfection of lung tissue
11/01/2001	US20010036452 Interleukin-1 muteins useful as vaccine adjuvants
11/01/2001	US20010036449 Therapy for dry eye
11/01/2001	US20010036445 Method of making chewing gum containing colloidal bismuth subcitrate
11/01/2001	US20010036443 Respiratory system disorders
11/01/2001	EP1144642A3 Compounds and methods for treatment and diagnosis of chlamydial infection
11/01/2001	CA2690018A1 Methods and compositions for the prevention and treatment of anemia
11/01/2001	CA2410024A1 Identification and uses of a hyaluronan receptor
11/01/2001	CA2407494A1 Novel proteins and nucleic acids encoding same
11/01/2001	CA2407493A1 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
11/01/2001	CA2407449A1 Novel compounds
11/01/2001	CA2407167A1 Thrombopoietin receptor modulating peptide
11/01/2001	CA2407086A1 Integrin/adhesion antagonists
11/01/2001	CA2407083A1 Apo-ai/aii peptide derivatives
11/01/2001	CA2407074A1 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
11/01/2001	CA2407053A1 Pneumovirus ns proteins antagonize the interferon (ifn) response
11/01/2001	CA2407010A1 Use of recombinant gastric lipase for treating functional dyspepsia
11/01/2001	CA2406949A1 Use of particulate vectors in immunomodulation
11/01/2001	CA2406855A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
11/01/2001	CA2406839A1 G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
11/01/2001	CA2406725A1 Edg8 receptor, its preparation and use
11/01/2001	CA2406660A1 Heteromultimeric ion channel receptor and uses thereof
11/01/2001	CA2406639A1 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001	CA2406532A1 Macrocyclic ns-3 serine protease inhibitors of hepatitis c virus compri sing alkyl and aryl alanine p2 moieties
11/01/2001	CA2406399A1 Human kinases
11/01/2001	CA2406264A1 Protein phosphatases
11/01/2001	CA2406073A1 A protein kinase c variant to alter memory
11/01/2001	CA2405983A1 Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferation of cancer cell using the expression vector
11/01/2001	CA2405961A1 Bispecific molecules and uses thereof
11/01/2001	CA2405680A1 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
11/01/2001	CA2405632A1 Intrathecal administration of rituximab for treatment of central nervous system lymphomas
11/01/2001	CA2405551A1 Diagnostic and therapeutic methods using the h37 tumor suppressor gene
11/01/2001	CA2405138A1 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors
11/01/2001	CA2405103A1 Chemical modification of mammalian urine and blood
10/2001
10/31/2001	EP1149916A2 Defective Adenoviruses and corresponding transcomplementant cell lines
10/31/2001	EP1149913A1 Cytokine immunoconjugates
10/31/2001	EP1149910A1 Pharmaceutical composition for treating papillomavirus tumours and infection
10/31/2001	EP1149909A1 Methods for regulating protein conformation using molecular chaperones
10/31/2001	EP1149908A1 TGF-beta type receptor cDNAs and uses thereof
10/31/2001	EP1149906A1 Thrombopoietin receptor modulating peptide

1 ... 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 ... 3163